A phase IA/IB, two arm, multi-center, open-label, dose escalation study of oral LBH589 [panobinostat] alone and in combination with IV docetaxel and oral prednisone in hormone refractory prostate cancer (HPRC)
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Docetaxel; Panobinostat; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- 07 Feb 2007 New trial record.